Trial Profile

Anti-Inflammatory, Insulin-Sensitizing Agent for Treatment of Cognitive Decline Due to Degenerative Dementias

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 21 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bezisterim (Primary)
Indications Alzheimer's disease; Dementia; Mild cognitive impairment
Focus Therapeutic Use

Most Recent Events

26 Jul 2024 Results assessing neurophysiological and neuropsychological effects of NE3107 published in the Medicine
31 Aug 2023 According to a BioVie media release, the company leadership team and Key Opinion Leader (KOL) Steven E. Arnold, MD will discuss overview of trial results in a virtual KOL event on NE3107 ahead of the upcoming Phase 3 results in Alzheimers Disease on Thursday, September 7, 2023.
20 Jul 2023 Results presented at the Alzheimer's Association International Conference 2023

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com